Investors Overview

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases.

Collegium has developed a novel, patented, abuse-deterrent technology platform, DETERx®, designed to provide extended-release drug delivery, while safeguarding against common methods of abuse and tampering including crushing, chewing, heating and injecting.

Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. While abuse of Xtampza ER is still possible, FDA has determined that the product has abuse-deterrent properties. The Xtampza ER label supports alternate administration options, including, sprinkling the capsule contents on soft foods or into a cup, and then directly into the mouth, or through a gastrostomy or nasogastric feeding tube.

Stock Quote

Copyright West LLC. Minimum 15 minutes delayed.

More »

Recent News

Date Title  
Toggle Summary Collegium Provides Full-Year 2019 Financial Guidance
– Xtampza ER Revenue Expected in the Range of $95 Million to $105 Million – Nucynta Franchise Revenue Expected in the Range of $200 Million to $210 Million – Total Operating Expenses Expected in the Range of $125 Million to $135 Million STOUGHTON, Mass. , Jan.
Toggle Summary Collegium to Present at Upcoming Investor Conferences
STOUGHTON, Mass. , Nov. 12, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative and differentiated products for people suffering from
Toggle Summary Collegium Reports Third Quarter Financial Results
Net Product Revenues were $70.2 million for the third quarter of 2018, a 487% increase versus third quarter of 2017 Thirteen exclusive ER oxycodone formulary wins announced for Xtampza ER effective January 1, 2019 Cash increased by $6.0 million , to $139.8 million as of September 30, 2018 ; raising
Upcoming Events
There are currently no events scheduled.
More »